Recent Insider Selling: JPMorgan Chase (NYSE:JPM), Micron Technology (NASDAQ:MU), Gilead Sciences (NASDAQ:GILD), Arena Pharmaceuticals (NASDAQ:ARNA)

JPMorgan Chase & Co. (NYSE:JPM) EVP Gordon Smith sold 71,952 shares of the stock in a transaction that occurred on Monday, April 14th. The stock was sold at an average price of $54.91, for a total value of $3,950,884.32. Following the transaction, the executive vice president now directly owns 143,905 shares of the company’s stock, valued at approximately $7,901,824. JPMorgan Chase & Co. (NYSE:JPM) stock … Continue reading Recent Insider Selling: JPMorgan Chase (NYSE:JPM), Micron Technology (NASDAQ:MU), Gilead Sciences (NASDAQ:GILD), Arena Pharmaceuticals (NASDAQ:ARNA)

John Meady04/1704/17

Small Cap Recent Insider Selling: Arena Pharmaceuticals (NASDAQ:ARNA), Zeltiq Aesthetics (NASDAQ:ZLTQ), Entravision Communication (NYSE:EVC), RetailMeNot Inc (NASDAQ:SALE)

Arena Pharmaceuticals Inc (NASDAQ:ARNA) Director Tina Susan Nova sold 35,000 shares of the stock on the open market in a transaction dated Monday, April 14th. The shares were sold at an average price of $6.22, for a total value of $217,700.00. Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) stock performance was 3.25% in last session and finished the day at $6.35. Traded volume was 6.98million shares in the … Continue reading Small Cap Recent Insider Selling: Arena Pharmaceuticals (NASDAQ:ARNA), Zeltiq Aesthetics (NASDAQ:ZLTQ), Entravision Communication (NYSE:EVC), RetailMeNot Inc (NASDAQ:SALE)

Mark Doerr04/1604/16

Biotech Active runners: Arena Pharmaceuticals (NASDAQ:ARNA), Halozyme Therapeutics (NASDAQ:HALO), Gildan Activewear (NYSE:GIL), Ariad Pharmaceuticals (NASDAQ:ARIA)

Sales of the Arena Pharmaceuticals Inc (NASDAQ:ARNA) anti-obesity drug Belviq have closed out the quarter on a positive note. Sales improved throughout the quarter and are pacing well ahead of the previous quarter. Though this week’s sales only take us to March 28th, there is enough here for us to assess the sales activity, project some revenue, and look to the pace. Arena Pharmaceuticals, Inc. … Continue reading Biotech Active runners: Arena Pharmaceuticals (NASDAQ:ARNA), Halozyme Therapeutics (NASDAQ:HALO), Gildan Activewear (NYSE:GIL), Ariad Pharmaceuticals (NASDAQ:ARIA)

Jason Knox04/0704/07

Biotech Most Active Stocks: Gilead Sciences (NASDAQ:GILD), Ariad Pharmaceuticals (NASDAQ:ARIA), Arena Pharmaceuticals (NASDAQ:ARNA), MannKind Corporation (NASDAQ:MNKD)

Gilead Sciences, Inc. (NASDAQ:GILD) was active yesterday as one Bloomberg reporter thinks he has another take on the recent Waxman letter. Drew Armstrong — via his own Twitter account — said Gilead execs had a meeting scheduled with Waxman all along and the letter just seemed like Waxman was making an effort to drag them in. Gilead Sciences, Inc. (NASDAQ:GILD) stock performance was 3.37% in … Continue reading Biotech Most Active Stocks: Gilead Sciences (NASDAQ:GILD), Ariad Pharmaceuticals (NASDAQ:ARIA), Arena Pharmaceuticals (NASDAQ:ARNA), MannKind Corporation (NASDAQ:MNKD)

Mark DeFrance04/0104/01

Biotech Most Active Stocks: Gilead Sciences (NASDAQ:GILD), EXACT Sciences Corporation (NASDAQ:EXAS), Endocyte (NASDAQ:ECYT), Arena Pharmaceuticals (NASDAQ:ARNA)

Gilead Sciences Inc. (NASDAQ:GILD) announced that it has elected to settle its conversion obligations in connection with any 1.00% Senior Convertible Notes due 2014 (the “Notes”) submitted for conversion on or after February 1 2014 entirely in cash. Gilead Sciences, Inc. (NASDAQ:GILD) stock performance was -4.01% in last session and finished the day at $68.55. Traded volume was 29.25million shares in the last session and … Continue reading Biotech Most Active Stocks: Gilead Sciences (NASDAQ:GILD), EXACT Sciences Corporation (NASDAQ:EXAS), Endocyte (NASDAQ:ECYT), Arena Pharmaceuticals (NASDAQ:ARNA)

Kevin Long03/3103/31

Biotech Active Stocks: Inovio Pharmaceuticals (NYSEMKT:INO), Ariad Pharmaceuticals (NASDAQ:ARIA), MannKind Corporation (NASDAQ:MNKD), Arena Pharmaceuticals (NASDAQ:ARNA)

Inovio Pharmaceuticals Inc (NYSEMKT:INO) reported financial results for the fourth quarter and year ended Dec. 31, 2013. Total revenue was $1.7 million and $13.5 million for the quarter and year ended December 31, 2013, as compared to $1.1 million and $4.1 million for the same periods in 2012. Inovio Pharmaceuticals Inc (NYSEMKT:INO) stock performance was -7.98% in last session and finished the day at $3.23. … Continue reading Biotech Active Stocks: Inovio Pharmaceuticals (NYSEMKT:INO), Ariad Pharmaceuticals (NASDAQ:ARIA), MannKind Corporation (NASDAQ:MNKD), Arena Pharmaceuticals (NASDAQ:ARNA)

Colin Pettis03/2603/26